Adenovirus expressing herpes simplex virus-thymidine kinase (HSV-TK) sensitizes internal rat glioma cells to radiation in combination with acyclovir (ACV). However, relatively high concentrations of ACV (Ͼ10 M) are required to obtain significant radiosensitization. Serum levels rarely reach more than the lower micromolar range, preventing the full use of this genetic approach to radiosensitize cells in vivo. To better use the lower concentrations of ACV available in sera, we constructed an adenovirus expressing a mutant HSV-TK (HSV-TK (75)) isolated for its ϳ20 times greater sensitivity to ACV than wild-type (wt) HSV-TK. We demonstrate that rat RT2 glioma cells infected with adenovirus AdCMV-TK(75) and exposed to either ACV or ganciclovir become more sensitive to lower concentrations (1-3 M) of the drugs compared with cells infected with AdCMV-TK(wt), which expresses wt HSV-TK. Most importantly, the RT2 cells become more sensitive to low doses (2-4 Gy) of 60 Co radiation than cells infected with an adenovirus expressing wt HSV-TK. This sensitization is accompanied by an increased rate of apoptosis. In summary, we show that infection of rat glioma cells with an adenovirus expressing a mutant HSV-TK sensitizes the cells to low doses of radiation after exposure to ACV at lower concentrations than those required for wt HSV-TK. This finding suggests that this mutant adenovirus may improve the in vivo efficacy of HSV-TK-based cancer gene therapy approaches. Cancer Gene Therapy (2000) 7, 879 -884
C
ancer gene therapy approaches based on herpes simplex virus-thymidine kinase (HSV-TK) show promise for the treatment of glioma. [1] [2] [3] We demonstrated recently that rat glioma cells are sensitized to radiation both in vitro and in vivo after infection with an adenovirus expressing HSV-TK and exposure to the halogenated pyrimidine bromodeoxycytidine. 4 The clinically used anti-herpetic drug acyclovir (ACV) also radiosensitizes tumor cells in combination with HSV-TK (our unpublished observations). 5, 6 However, one limiting factor for efficient clinical use of HSV-TK and ACV is the extent to which HSV-TK can use the lower concentrations of ACV present in sera, which are only in the lower micromolar range.
To determine whether a mutant form of HSV-TK performs better than wild-type (wt) HSV-TK to radiosensitize cells, we made an adenovirus expressing a mutant form of HSV-TK that is ϳ20 times more sensitive to ACV than is wt HSV-TK and tested whether infected rat RT2 glioma cells become more sensitive to radiation when exposed to low concentrations of ACV. 7 We found that cells infected with the mutant HSV-TK(75) adenovirus expressed HSV-TK protein at a level that was similar to that seen for cells infected with the wt HSV-TK adenovirus. However, cells infected with the mutant were significantly more sensitive to ACV in the 1-to 3-M range and, most importantly, these cells also were significantly more sensitive to radiation than were cells expressing wt HSV-TK.
MATERIALS AND METHODS

Cell culture
RT2 cells (a rat glioma cell line derived from Fischer 344 rats 8 ) that form tumors with features typical of human glioblastoma 9 were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum supplemented with penicillin/streptomycin. 4 Infected cells were exposed to Zovirax/ACV (manufactured by Glaxo Wellcome, Chapel Hill, NC) or ganciclovir (GCV) (kindly provided by Syntex, Palo Alto, Calif) added to the medium. Cells were irradiated in medium with a 60 Co ␥ irradiator (Picker Zonegard V4 M60; Picker Interational, Cleveland, Ohio) set at 1 Gy/minute. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay. 10 Terminal deoxynucleotidyltrans-ferase-mediated deoxyuridine triphosphate nick end labeling assays were carried out with an ApopTag Direct kit from Oncor (Gaithersburg, Md), according to the manufacturer's instructions, to provide a measurement of apoptosis.
Adenovirus
Adenovirus was made in bacteria essentially as described elsewhere. 11 Mutant HSV-TK(75) cDNA and the corresponding wt gene were kindly provided by Margaret Black (University of Washington, Seattle, Wash). 7 To make adenovirus that expresses wt or mutant HSV-TK(75) under control of the cytomegalovirus promoter, we cloned a 1.4-kb NcoI fragment from either pET23d:HSVTK or pET23d:75 7 into the BamHI site of pZERO-TGCMV by blunt-end ligation after filling in the 5Ј-overhangs with Klenow polymerase. In the process, both the NcoI and BamHI sites are restored. Adenovirus (dLE1, dLE3) was then made in Escherichia coli as described previously.
11
Adenovirus expressing wt HSV-TK (AdCMV-TK(wt)), mutant HSV-TK(75) (Ad-CMV-TK(75)), and AdCMV (empty vector) were grown in 293 cells as described previously 12 and purified by double CsCl gradient centrifugation followed by dialysis against 13% glycerol in phosphate-buffered saline. Virus was snap frozen in liquid nitrogen and stored at Ϫ70°C until further use. Virus titering was done using a direct immunofluorescence assay (Light Diagnostics, Temecula, Calif) and a standard plaque assay. We routinely achieve titers of 2 ϫ 10 11 plaque-forming units/mL.
Protein analysis
Western blot analysis was carried out essentially as described previously 13 with rabbit polyclonal anti-HSV-TK antibody (Ab) at a 1/5000 dilution followed by a 1/2000 dilution of goat anti-rabbit immunoglobulin G coupled to alkaline phosphatase (Oncogene Science, Manhasset, NY) and developing with CDP-Star (Tropix, Bedford, Mass).
Statistical analysis
Statistical analysis was carried out by three-way variance F test analysis with SPlus (version 4.5; MathSoft, Cambridge, Mass) computer software.
RESULTS
Construction and testing of an adenovirus expressing mutant HSV-TK(75)
To test for the expression of HSV-TK in mammalian cells, we infected rat RT2 glioma cells with an adenovirus expressing the LacZ reporter, 4 or the newly constructed AdCMV-TK(wt) and AdCMV-TK(75) virus. This experiment was necessary to rule out the possibility that differences in toxicity between the two HSV-TK viruses were not due to the differential expression/steady-state level of HSV-TK between wt and mutant HSV-TK(75) virus. Using a polyclonal rabbit Ab raised against HSV-TK (kindly provided by Margaret Black, University of Washington) in a Western blot experiment, we were able to demonstrate that AdCMV-TK(wt) and AdCMV-TK(75) virus expressed the 44-kDa HSV-TK protein at similar levels (Fig 1) . In stably transfected hamster cells, mutant HSV-TK (75) protein levels were approximately half those of wt HSV-TK. 7 Mutant HSV-TK(75) sensitizes RT2 cells to GCV and ACV more efficiently than wt HSV-TK We subsequently determined whether infection of RT2 cells with the adenovirus expressing mutant HSV-TK(75) was able to sensitize RT2 cells to GCV and ACV more efficiently than cells infected with virus expressing wt HSV-TK. At 2 days postinfection, infected cells were exposed to increasing concentrations (1-100 M) of either GCV or ACV. As a control, we used an adenovirus (AdCMV) carrying no trans-gene. We found that GCV or ACV had little to no effect on control AdCMVinfected RT2 cells (Fig 2, top) . Infection with AdCMV-TK(wt) resulted in significant sensitization with both GCV and ACV (Fig 2, middle) . Cell killing with GCV was more effective than with ACV, in agreement with a lower K m for GCV. 14, 15 As with previous results, 7 we found that mutant HSV-TK(75) sensitized RT2 cells to GCV and ACV better than wt HSV-TK (Fig 2, bottom) . These results demonstrate that mutant HSV-TK(75) is more effective than wt HSV-TK in killing RT2 cells in combination with either GCV or ACV, in agreement with results obtained with stably transfected hamster cells expressing wt or mutant HSV-TK(75). 7 Mutant HSV-TK(75) in combination with ACV radiosensitizes RT2 cells more efficiently than wt HSV-TK To determine whether mutant HSV-TK(75) was also more effective than wt virus as a radiosensitizer in combination with ACV, we infected RT2 cells and after 2 days, provided ACV at either 1 or 3 M. After another day, the cells were exposed to either 2 or 4 Gy of radiation followed by cell proliferation/survival assay 5 days later. Without any radiation, we found that Ad-CMV-TK(wt) did not sensitize the cells significantly, whereas HSV-TK(75) reduced cell growth by ϳ25% at 1 M and ϳ50% at 3 M (Fig 3, top) . Radiation further sensitized both wt HSV-TK-and HSV-TK(75)-infected cells in a dose-dependent fashion (Fig 3, middle and  bottom) . The sensitizer enhancement ratios (SERs) were calculated (Table 1) . A significant (P Ͻ .0001) difference between the SER obtained with wt and mutant HSV-TK(75) is notable, in particular with the lower doses of 2 Gy and 1 M ACV (1.1 vs. 1.4). This result demonstrates that mutant HSV-TK(75) expressed from an adenovirus performs significantly better than wt HSV-TK in radiosensitizing RT2 cells in combination with ACV at clinically relevant radiation doses and low concentrations of ACV.
Mutant HSV-TK(75) potentiates radiosensitization through increased rate of apoptosis
To establish the mode of death that occurs after RT2 cells are exposed to these treatments, we determined the level of apoptosis. Recently, we demonstrated that RT2 cells undergo apoptosis at a significantly higher rate when exposed to the halogenated pyrimidine bromodeoxycytidine and infection with an adenovirus expressing HSV-TK, and radiation significantly potentiated this effect. 4 As described above, RT2 cells were infected with Figure 2 . Mutant HSV-TK(75) sensitizes RT2 cells to GCV and ACV more efficiently than wt HSV-TK. Rat RT2 cells were infected with AdCMV (empty vector), AdCMV-TK(wt), or AdCMV-TK(75). At 2 days postinfection, cells were trypsinized, serially diluted, seeded in microtiter plates, and exposed to various doses of ACV or GCV. After 5 days, the plates were processed for growth/toxicity by MTT assay. 10 Values were normalized to values from cells that were infected but not treated with GCV or ACV.
either one of the two HSV-TK adenoviruses or an empty control virus (AdCMV) and then exposed to 3 M ACV for 20 hours followed by low doses of radiation (2 or 5 Gy). The extent of apoptosis was determined 20 hours after radiation (40 hours after ACV treatment). We found that control-infected cells did not undergo significant apoptosis after exposure to ACV irrespective of radiation. Cells infected with AdCMV-TK(wt) underwent apoptosis after exposure to both ACV and radiation (4 -6%), but not in the absence of radiation.
However, cells infected with AdCMV-TK(75) and exposed to ACV showed ϳ9% apoptotic cells without radiation and ϳ14% with either 2 or 5 Gy of radiation. No apoptosis was detected without ACV or radiation with any of the viruses.
This result demonstrates that, similar to our previous results with bromodeoxycytidine and HSV-TK adenovirus infection of RT2 cells, 4 ACV treatment in combination with radiation also significantly increases apoptosis in cells infected with HSV-TK adenovirus. An apoptotic mechanism of cell death also has been suggested for HSV-TK-mediated killing of glioma with the drug GCV. 16, 17 In addition, mutant HSV-TK(75) performed significantly better, almost doubling the number of cells undergoing apoptosis compared with infection with wt HSV-TK virus. Most importantly, an ϳ2-fold potentiation of drug-induced apoptosis with radiation was clearly noticeable with mutant HSV-TK(75). Furthermore, little to no increase in apoptotic cells was noticed by increasing radiation from 2 to 5 Gy, suggesting that the potentiation effect has already peaked at 2 Gy. This finding is important because 2 Gy is the dose used clinically. Average values obtained from the data shown in Figure 3 were used to determine SER values. SER is defined as the ratio between growth/survival without radiation divided by survival with radiation. Significant (P Ͻ .0001) differences were found for the ACV and radiation dose effects for each of the two viruses, and, most importantly, between the AdCMV-TK(wt) and AdCMV-TK(75) adenovirus.
DISCUSSION
In recent years, the potential use of HSV-TK-based sensitization approaches for the treatment of various types of cancers, including malignancies of the central nervous system (CNS), has been demonstrated with both retrovirus and adenovirus vector technology, 1,2,18 with some studies entering clinical trials. 19 It was demonstrated recently that rat glioma 9L cells infected with a retrovirus expressing HSV-TK significantly radiosensitized cells in combination with ACV in vitro, and extended the life of syngeneic Fisher 344 rats implanted cerebrally with HSV-TK-expressing 9L glioma cells that were irradiated. 5, 18 However, the in vitro studies used relatively high concentrations of ACV (10 g/mL or 45 M) to achieve an SER of 1.6. 5, 18 In this study, we show that in vitro we can significantly (P Ͻ .0001) radiosensitize rat RT2 glioma cells by infection with an adenovirus expressing wt HSV-TK at low concentrations of 1-3 M ACV (SER ϭ 1.2-1.4). Most importantly, we demonstrate with an adenovirus expressing mutant HSV-TK that we can significantly (P Ͻ .0001) increase this SER further to 1.5-1.6. This increased radiosensitization is accompanied by an increased rate of apoptosis.
There is presently a lack of information regarding the relative potency of GCV versus ACV in combination with HSV-TK-based adenovirus delivery for the treatment of glioma. Generally, GCV has been the preferred prodrug in HSV-TK-based cancer gene therapy studies because of the ϳ10-fold better K i value of GCV for HSV-TK compared with ACV (45 M and Ͼ400 M, respectively). 14, 15 However, the relatively poor performance of GCV against herpes disease of the CNS is related to the low lipophilicity of GCV and its inability to effectively penetrate the blood-brain barrier (BBB), with a BBB ratio of only 0.063. 20 Steady-state ACV serum levels after intravenous infusion are in the range of 6 -20 g/mL, and 25-70% of these serum levels can be achieved in the CNS. 21 The significantly better BBB properties of ACV make this drug the preferred treatment for herpes-associated encephalitis 21 and suggest that it may perform better than GCV for the treatment of glioma with HSV-TK-based approaches.
In summary, our study has clearly demonstrated that an adenovirus expressing mutant HSV-TK(75) performs significantly better than wt HSV-TK in sensitizing glioma cells to low doses of ACV, which are readily achievable clinically. Furthermore, mutant HSV-TK(75) virus and ACV also perform better than wt HSV-TK in combination with radiation. The use of this mutant HSV-TK adenovirus should improve the efficacy of HSV-TK-based cancer gene therapy.
